Source: NuGen.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Common shares of NuGen Medical Devices (NGMD) have begun trading on the OTCQB under the symbol NGMDF
  • The company’s common shares will continue to trade on the TSX Venture Exchange under the symbol NGMD
  • Trading on the OTCQB will provide NuGen with added visibility to U.S. investors
  • The company also reports that it is awaiting approval for its application for DTC eligibility
  • NuGen is a specialty medical device company
  • NuGen Medical Devices (NGMD) is up 9.52 per cent on the day, trading at C$0.115 per share at 1:30 pm ET

Common shares of NuGen Medical Devices (NGMD) have begun trading on the OTCQB under the symbol NGMDF.

The company’s common shares will continue to trade on the TSX Venture Exchange under the symbol NGMD.

“Commencing trading on the OTCQB venture exchange is an important milestone for NuGen,” stated Michael Wright, CEO of NuGen.

“Having our common shares available on the OTCQB will increase accessibility for American investors interested in directly participating in NuGen’s growth with the same ease as their Canadian counterparts.”

The OTCQB Venture Market is for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their financial reporting and undergo an annual verification and management certification process.

The company also reports that it is awaiting approval for its application for DTC eligibility for electronic settlement and transfer of its common shares in the United States.

NuGen is a specialty medical device company developing needle-free technologies and other innovative medical delivery products.

NuGen Medical Devices (NGMD) is up 9.52 per cent on the day, trading at C$0.115 per share at 1:30 pm ET.


More From The Market Herald
Emerald Health Therapeutics Inc. - Director & Chairman, Jim Heppell.

" Emerald Health (CSE:EMH) shareholders approve merger

Emerald Health Therapeutics (EMH), has received shareholders’ approval for the proposed plan of arrangement with Skye Bioscience Inc.
Mydecine Innovations Group - CEO, Josh Bartch.

" Mydecine (NEO:MYCO) raises $244K and shifts management team

Mydecine Innovations Group (MYCO) has signed a common share subscription agreement with a third-party investor for proceeds up to $244,99.50.
PharmaDrug - CEO, Daniel Cohen

" PharmaDrug (CSE:PHRX) completes milestone to support cGMP production of PD-001

PharmaDrug (PHRX) has laid the groundwork to support cGMP production of cepharanthine-2HCL for use in the drug product production of PD-001.

" Hemostemix (TSXV:HEM) announces $1.5M non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 5 million units for gross proceeds of up to $1.5 million.